25th Annual Scientific Session of IWAA

Park City, UT US

Thank you for joining the IWAA's 25th Annual Scientific Session. Held August 3rd through the 5th, 2023, at the Grand Summit Hotel in Park City, Utah. IWAA strives to provide a maximum number of CME credits in little out-of-the-office time at a good value registration fee. Speakers, nationally recognized in their specialties, will present topics that are clinically relevant.

Credit claiming will be available through August 31, 2024. Credit requests on or after September 1, 2024 will be subject to an administrative fee.

Please visit www.IWAA.org for more information

Target Audience

  • Allergist/immunologists
  • Fellows-in-training
  • Nurse Practitioners
  • Nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the differences between aspirin therapy and biologic therapies
  • Describe differences between biologic therapies in AERD
  • Describe new updates in our understanding of AERD pathophysiology
  • Review concept of pathogenesis of nasal polyposis
  • Name the dominant immune abnormalities in nasal polyposis
  • Describe updated guidelines regarding treatment of nasal polyposis
  • Discuss the role of genetic testing in patients with inborn errors of immunity.
  • Identify patients that would benefit from genetic testing.
  • Review American College of Medical Genetics variant nomenclature.
  • Compare various methods of genetic testing.
  • Develop a step-wise approach for the interpretation of variants of uncertain significance utilizing free available online tools.
  • Describe non-infectious manifestations of inborn errors of immunity.
  • Identify patients with autoimmunity and/or immunodysregulation that would benefit from screening for an inborn error of immunity.
  • Discuss the benefits of making a specific IEI diagnosis.
  • Differentiate between various causes of hypogammaglobulinemia.
  • Identify risk factors associated with hypogammaglobulinemia in patients receiving B cell depleting therapies.
  • Utilize biomarkers to help guide management in patients with primary and secondary humoral immunodeficiency.
  • Assess available data on fatalities in food-induced anaphylaxis
  • Discuss risks factors of fatal anaphylaxis
  • Evaluate factors to mitigate fatalities
  • Identify limitations in current testing for food allergies
  • Determine when food challenges should be performed based on history and testing
  • Discuss novel testing strategies
  • Identify the importance of urban vegetation organization and diversity in allergy patient exposure.
  • Recognize the importance of unnatural distribution of allergenic plants compared to natural systems that do not adequately reflect true patient exposure.
  • Understand the scope of mast cell activation disorders
  • Identify  mast cell activation disorders with their associated endotypes
  • Evaluate the role of KIT D816V mutation and TPSAB1 genotyping in the diagnosis of mast cell activation disorders
  • Discuss current and future management and treatment options for mast cell activation disorders
  • Explain the pathophysiology of atopic dermatitis to the selection of treatment for patients with atopic dermatitis
  • Recognize indications for new therapies for atopic dermatitis and appropriate monitoring for potential adverse events
  • Discuss emerging therapies for atopic dermatitis
  • Recognize diseases that may be misdiagnosed as atopic dermatitis
  • Utilize appropriate testing in patients where the diagnosis of atopic dermatitis is in question
  • Define the “patient centered practice” and understand its value (beyond financial value)
  • List the steps necessary to build a patient centered practice
  • Understand the importance of a practice mission in relation to the practice-centered practice
  • List techniques you can use to empower staff to work as a team in support of your practice mission
  • Understand the new new USP 797 requirements.
  • Understand why it is critical to meet the USP standards.
  • Discuss requirements for compliant with USP 797 requirements.
  • Summerize the impact of neglected tropical diseases and COVID-19 among unvaccinated populations in the United States and globally.
  • Report on global failures or weaknesses in vaccinating low- and middle-income countries especially in Latin America, Southeast Asia, and Africa, and our Texas Children’s Hospital recombinant protein vaccines now in use in India and Indonesia where they are known as CORBEVAX and INDOVAC, respectively.
  • Summarize the origins of rising antivaccine sentiments and its recent shifts.
  • Discuss the pathophysiology of asthma
  • Understand the predicative value and limitations of current biomarkers
  • Understand current data of approved biologics and molecules that might be targets for the future
  • Understand the similarities and differences of biologics in asthma
Available credit: 
  • 14.25 Attendance
    Attendance credit.
  • 14.25 CME
    CME credit.
Course opens: 
Course expires: 

25th Annual Scientific Session of IWAA
“New Advances in Allergy, Asthma and Immunology”
August 3-5, 2023
The Grand Summit Hotel, Park City, Utah

Thursday, August 3rd, 2023

4:30 PMRegistration Opens
6:00-7:00 PMWelcome Reception
7:00-8:30 PMNew Frontiers: Treatment of Chronic Sinusitis with Nasal Polyps with Biologics - Andrew White, M.D.

Friday, August 4th, 2023

7:00 AMRegistration Opens
7:00-8:00 AMExhibits Open/Posters/Continental Breakfast
7:00-7:55 AMIndustry Sponsored Product Theater Breakfast
7:55 AMWelcome - Program Chairperson
8:00-8:45 AMNew and Emerging Therapies for Atopic Dermatitis – Mark Boguniewicz, M.D.
8:45-9:30 AMAERD Treatment: Aspirin Desensitization or Biologics – Andrew White, M.D.
9:30-9:45 AMPanel Discussion
9:45-10:15 AMExhibits/Posters/Refreshments
10:15-11:00 AMChallenging Cases from the Eczema Clinic – Mark Boguniewicz, M.D.
11:00-11:45 AMUpdate on Mastocytosis and Mast Cell Activation Syndrome – Mariana Castells, M.D., Ph.D. (Live, virtual presentation)
11:45-12:00 PMPanel Discussion
Noon - 1:00 PMIndustry Sponsored Product Theater Luncheon
1:15-2:15 PM PMGlobal Vaccines: The Science vs The Anti-Science – Peter Hotez, M.D., Ph.D. (Live, virtual presentation)
2:15-3:00 PM PMThe Role and Interpretation of Genetic Testing in the Diagnosis and Care of the Immunodeficient Patient – Benjamin Prince, M.D., MSCI
3:00-3:30 PMExhibits/Posters/Refreshments
3:30-4:30 PMClinical Remission in Asthma – Rohit Katial, M.D.
4:30-6:15 PMIndustry Sponsored Product Theaters

Saturday, August 5th, 2023

7:00-8:00 AMExhibits Open/Posters/Continental Breakfast
8:00-8:45 AMDiagnostic Tools for Food Allergies – Jay Lieberman, M.D.
8:45-9:30 AMFactors to Consider When Choosing a Biologic for Refractory Asthma – Rohit Katial, M.D.
9:30-9:45 AMPanel Discussion
9:45-10:15 AMExhibits/Posters/Refreshments
10:15-11:00 AMAnaphylaxis and Fatalities in Food Allergies: What We Need to Tell our Patients –Jay Lieberman, M.D.
11:00-11:45 AMPearls and Pitfalls in the Diagnosis of the Immunodeficient Patient for the Community Allergist – Benjamin Prince, M.D., MSCI
11:45-12:00 PMPanel Discussion
Noon - 1:00 PMIndustry Sponsored Product Theater Luncheon
1:15-2:15 PMBotanical Allergy Potpourri – Jim Thompson, Ph.D.
2:15-2:30 PMRefreshment Break
2:30-4:30 PMPractice Management Symposium: Patient Centered Allergy Practice Update USP 797 Extract Compounding New Rules - Mohamed Yassin, M.D.
7:00 PMClosing Event
Grand Summit Hotel
4000 Canyons Resort Drive
Park City, UT 84098
United States

Please make room reservations directly withThe Grand Summit Hotel by calling
855-332-1601, then option 1, followed by option 3.

The rooms are held under IWAA Meeting 2023 or code BPCIAA23.

Planning Committee

Ron England, MD FAAAAI
Spokane Allergy and Asthma, Spokane, WA
Relevant relationships: None



Mark Boguniewicz, MD
National Jewish Health, Denver, CO
Relevant relationships: Incyte, Janssen, Leo, Lilly, Pfizer, Regeneron, Sanofi-Genzyme (advisory board); Abbvie (consultant); Incyte, Regeneron (research grant)

Rohit Katial, MD FAAAAI
National Jewish Health, Denver, CO
Relevant relationships: None

Jay Lieberman, MD FAAAAI
The University of Tennessee, Memphis, TN
Relevant relationships: None

Andrew A. White, MD FAAAAI
Scripps Clinic, San Diego, CA
Relevant relationships: ALK, AstraZeneca, GSK, OptiNose (advisory board); AstraZeneca, Amgen, OptiNose, Blueprint, GSK (speaker)


Content Reviewers

Gloria Akan, MD
ENTAA Care, Glen Burnie, MD
Relevant relationships: None

Pamela Steele, MSN CPNP AE-C
University of North Carolina at Chapel Hill, Chapel Hill, NC
Relevant relationships: None

AAAAI Disclosure Policy

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

  • Employment. Name of employer and job title.
  • Financial interests. All organizations, other than the employer, from which the faculty member receives annual remuneration in any amount (including grants, honoraria and consulting fees).
  • Research interests. All organizations which support research projects for which the faculty member serves as an investigator.
  • Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
  • Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
  • Gifts. All organizations from which the faculty member have received a gift of any amount in the last year.
  • Other interests. All interests of the faculty member that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.


The information disclosed by the speakers, planning committee, and reviewers was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AAAAI and Aspen Allergy Conference. The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Claiming Period
Credit claiming for this activity will expire at 11:59 pm on August 31, 2024. Requests to claim credit on or after September 1, 2024 will be subject to an administrative fee.

Medium and Method of Physician Participation for a Live Activity
Follow these steps to complete the activity:

  1. Register for the activity.
  2. Review the CME and Disclosure information.
  3. View pre-meeting information and/or complete the pre-test (if applicable)
  4. Attend the meeting. Be sure to sign in so your attendance can be recorded.
  5. Return to the online meeting site after the meeting and complete the post-test (if applicable - you must achieve a score of 70% or higher on post-tests to claim credit)
  6. Complete the activity evaluation.
  7. Claim your credits. Enter only the number of credits earned based on your participation in the activity.
  8. Print or save your certificate.

Registration and credit claiming questions should be directed to cme@aaaai.org.

Available Credit

  • 14.25 Attendance
    Attendance credit.
  • 14.25 CME
    CME credit.


Please login or register to take this course.
By registering for this educational activity you are confirming that you have read the Privacy and Data Protection Notice and agree to the terms as outlined below:
Privacy and Data Protection Notice

The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.

By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration/Housing Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI.

The information you provide in the Registration/Housing Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI will also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law.

For courses/events with industry support and/or exhibitors, The AAAAI may disclose some information that is collected in the Registration Form such as your name, credentials, title/position, organization, and mailing address to exhibitors and industry supporters for marketing purposes such as to receive mailed literature. In addition to, but separate from, your consent regarding being contacted by exhibitors and industry supporters with mailed literature, when you visit sponsored areas within the virtual platform for an online event (such as, but not limited to, an exhibitor’s virtual exhibit booth), that organization will receive your personal contact information (name, credentials, title/position, organization, mailing address, phone number, email address and NPI number, if applicable). If you do not want to share your personal contact information with any/all of those organizations, please do not visit those areas within our virtual platform. By accessing any/all of those areas in our virtual platform, you are consenting to share your personal contact information with all organizations whose sponsored areas you visit in our virtual platform. If you attend this activity in person, and provide your contact information to an exhibitor or industry supporter (including allowing them to scan your name badge), you are consenting to share your personal contact information with that organization. You have the right to decline an exhibitor and/or industry supporter’s request for your personal contact information. AAAAI does not control the use or distribution of personal contact information transferred when you visit a sponsored area in the virtual platform or, if in person, when you share your personal contact information, and as such, AAAAI shall not be held responsible for any misuse of your personal data obtained by exhibitors or industry supporters in this manner. You have the right to ask the exhibitor or industry supporter questions about how they will use your personal data, how long it will be retained and if they will share information with third parties.

After you have submitted your personal contact information in the registration form, you may change your preferences for receiving emails by following the instructions below:
·    To change your preferences for receiving emails from AAAAI regarding future annual meetings and/or other in-person and online education programs, please visit http://aaaai.execinc.com/edibo/Profile
·    For events where industry support or exhibitions are involved please email cme@aaaai.org to change your consent to be contacted by the industry supporters and exhibitors of that activity.

NOTE: AAAAI  may be photographing this activity. These photographs, along with your name, may be used in AAAAI publications or on the AAAAI website. If you do not want your photo used, please inform the staff photographer at the time the photograph is taken. AAAAI may also be audio recording education sessions during this activity. If you verbally submit any questions for Question & Answer sessions (Q&A), you are agreeing to be recorded and to have that recording available in enduring materials. If you prefer not to be audio recorded, please submit any questions you have in writing.

I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration/housing request for this activity.

Required Hardware/software

One of the two latest versions of Google Chrome, Microsoft Edge, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.